# A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis

> **NCT02627768** · — · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 991 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** No Intervention

## Key facts

- **NCT ID:** NCT02627768
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-17
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 991 (ACTUAL)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02627768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02627768, "A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02627768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*